GB202007404D0 - Treatment for viral respiratory infections - Google Patents

Treatment for viral respiratory infections

Info

Publication number
GB202007404D0
GB202007404D0 GBGB2007404.3A GB202007404A GB202007404D0 GB 202007404 D0 GB202007404 D0 GB 202007404D0 GB 202007404 A GB202007404 A GB 202007404A GB 202007404 D0 GB202007404 D0 GB 202007404D0
Authority
GB
United Kingdom
Prior art keywords
treatment
respiratory infections
viral respiratory
viral
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2007404.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nasser Syed Muhammad Tahir
Original Assignee
Nasser Syed Muhammad Tahir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasser Syed Muhammad Tahir filed Critical Nasser Syed Muhammad Tahir
Priority to GBGB2007404.3A priority Critical patent/GB202007404D0/en
Publication of GB202007404D0 publication Critical patent/GB202007404D0/en
Priority to KR1020227044185A priority patent/KR20230053549A/ko
Priority to US17/999,266 priority patent/US20230192838A1/en
Priority to CA3179461A priority patent/CA3179461A1/en
Priority to ES21729598T priority patent/ES2982939T3/es
Priority to PL21729598.9T priority patent/PL4153302T3/pl
Priority to CN202180059606.0A priority patent/CN116406289A/zh
Priority to PCT/GB2021/051207 priority patent/WO2021234381A1/en
Priority to JP2022571157A priority patent/JP2023526853A/ja
Priority to EP21729598.9A priority patent/EP4153302B1/en
Priority to AU2021276614A priority patent/AU2021276614A1/en
Priority to HUE21729598A priority patent/HUE067327T2/hu
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2007404.3A 2020-05-19 2020-05-19 Treatment for viral respiratory infections Ceased GB202007404D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
HUE21729598A HUE067327T2 (hu) 2020-05-19 2021-05-19 Vírusos légúti fertõzések kezelése
ES21729598T ES2982939T3 (es) 2020-05-19 2021-05-19 Tratamiento para infecciones respiratorias virales
US17/999,266 US20230192838A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections
CA3179461A CA3179461A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections
KR1020227044185A KR20230053549A (ko) 2020-05-19 2021-05-19 바이러스성 호흡기 감염에 대한 치료
PL21729598.9T PL4153302T3 (pl) 2020-05-19 2021-05-19 Leczenie wirusowych zakażeń dróg oddechowych
CN202180059606.0A CN116406289A (zh) 2020-05-19 2021-05-19 病毒性呼吸道感染的治疗
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections
JP2022571157A JP2023526853A (ja) 2020-05-19 2021-05-19 ウイルス性呼吸器感染症の処置
EP21729598.9A EP4153302B1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections
AU2021276614A AU2021276614A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections

Publications (1)

Publication Number Publication Date
GB202007404D0 true GB202007404D0 (en) 2020-07-01

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2007404.3A Ceased GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections

Country Status (12)

Country Link
US (1) US20230192838A1 (https=)
EP (1) EP4153302B1 (https=)
JP (1) JP2023526853A (https=)
KR (1) KR20230053549A (https=)
CN (1) CN116406289A (https=)
AU (1) AU2021276614A1 (https=)
CA (1) CA3179461A1 (https=)
ES (1) ES2982939T3 (https=)
GB (1) GB202007404D0 (https=)
HU (1) HUE067327T2 (https=)
PL (1) PL4153302T3 (https=)
WO (1) WO2021234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
MX2013007067A (es) * 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US20230173021A1 (en) * 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases

Also Published As

Publication number Publication date
CN116406289A (zh) 2023-07-07
HUE067327T2 (hu) 2024-10-28
AU2021276614A1 (en) 2023-01-05
JP2023526853A (ja) 2023-06-23
WO2021234381A1 (en) 2021-11-25
PL4153302T3 (pl) 2024-10-07
US20230192838A1 (en) 2023-06-22
EP4153302A1 (en) 2023-03-29
EP4153302B1 (en) 2024-05-29
EP4153302C0 (en) 2024-05-29
CA3179461A1 (en) 2021-11-25
ES2982939T3 (es) 2024-10-21
KR20230053549A (ko) 2023-04-21

Similar Documents

Publication Publication Date Title
PL4157272T3 (pl) Remdesiwir do leczenia zakażeń wirusowych
ZA202006656B (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
SG11201702766YA (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
GB2596086B (en) Air treatment
GB2594617B (en) Air treatment system
IL279078A (en) Combination therapy for the treatment of hepatitis B viral infection
ZA202212662B (en) Use of compounds for treating viral infections
HUE067327T2 (hu) Vírusos légúti fertõzések kezelése
HUE049939T2 (hu) Liposzómák vírusfertõzések kezelésére
GB202015584D0 (en) Treatment for viral infection
EP3650015A4 (en) COMBINED DRUG PREPARATION FOR THERAPY OF VIRAL INFECTIONS
HUE065591T2 (hu) Gyógyszer fertõzõ betegségek kezelésére
GB202019421D0 (en) Air treatment system
GB202006160D0 (en) Treatment of viral infections
GB202004998D0 (en) Treatment of viral infections
GB202003232D0 (en) Treatment of viral infections
GB202315114D0 (en) Viral treatment
AU2021901731A0 (en) Inhalation formulation for the treatment of respiratory viral infections
GB202105509D0 (en) Viral infections
GB202020320D0 (en) Viral infections
GB202018571D0 (en) Viral infections
GB202018446D0 (en) Viral infections
GB202013976D0 (en) Viral infections
GB202010271D0 (en) Viral infections
GB202312669D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)